Randomised trial to determine the safety and efficacy of early vs deferred treatment of HIV

艾滋病毒的治疗代表着医学研究的奇迹般的成就。全球抗逆转录病毒药物的使用防止了大量的发病率和死亡率。然而，目前还不清楚这些药物是否应该用于艾滋病毒阳性、有早期艾滋病毒疾病但没有临床症状的人。START试验将对较早使用这些治疗与较晚使用这些治疗的风险-收益进行准确估计。它将立即影响世界各地的治疗指南，并为未来多年的研究提供信息。

Treatments for HIV represent a miraculous achievement of medical research. Global use of antiretroviral drugs has prevented substantial morbidity and mortality. However, it is unclear if these drugs should be used in people who are HIV positive with early HIV disease but no clinical symptoms. The START trial will result in a precise estimate of the risk-benefit for earlier versus later use of these treatments. It will immediately affect treatment guidelines around the world and inform future research for many years to come.